Im­mutep picks up more funds for LAG-3 on­col­o­gy and au­toim­mune stud­ies

Im­mutep has raised about $53 mil­lion to bankroll its LAG-3 drugs across on­col­o­gy and au­toim­mune dis­eases, giv­ing it a cash run­way to the first quar­ter of 2026.

The funds will bankroll a reg­is­tra­tional-di­rect­ed Phase III tri­al in lung can­cer, late-stage stud­ies in head and neck can­cer, and tri­al read­outs in metasta­t­ic and triple-neg­a­tive breast can­cer, chair Rus­sell Howard said in a state­ment. The cap­i­tal could al­so sup­port clin­i­cal en­try on the au­toim­mune front, the chair added.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER